Role of medium chain triglycerides (Axona®) in the treatment of mild to moderate alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 29, Issue 5, 2014, Pages 409-414

  Sharma, Alok ^a   Bemis, Marc ^a   Desilets, Alicia R ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b New Hampshire Dartmouth Psychiatric Research Center   (United States)

Author keywords

Alzheimer's disease; APOE4; Axona ; caprylidene; ketasyn; ketogenic agents; medium chain triglycerides; hydroxybutyrate

Indexed keywords

AC 1202; APOLIPOPROTEIN E4; MEDIUM CHAIN TRIACYLGLYCEROL; PLACEBO; KETONE BODY; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; BRAIN METABOLISM; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EMBASE; ENERGY RESOURCE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MEDLINE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ELEMENTAL DIET; METABOLISM;

ALZHEIMER DISEASE; FOOD, FORMULATED; HUMANS; KETONE BODIES; TRIGLYCERIDES;

EID: 84904413178     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513518650     Document Type: Review

References (43)

1. The Alzheimer's Association. http://www.alz.org/. Updated 2012. Accessed June 2, 2012.
2. Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for alzheimer's disease. Annu Rev Med. 2006 ; 57: 513-533
3. Birks J. Cholinesterase inhibitors for alzheimer's disease. Cochrane Database Syst Rev. 2006 ; (1). CD005593
4. Strittmatter WJ, Roses AD. Apolipoprotein E and alzheimer's disease. Annu Rev Neurosci. 1996 ; 19: 53-77
5. Bertram L, Tanzi RE. Thirty years of alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008 ; 9 (10). 768-778
6. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A meta-analysis. APOE and alzheimer disease meta analysis consortium. JAMA. 1997 ; 278 (16). 1349-1356
7. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in alzheimer's disease. Brain Pathol. 2008 ; 18 (2). 240-252
8. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and alzheimer disease: an evolving perspective. J Neuroinflammation. 2008 ; 5: 7
9. Mosconi L, De Santi S, Rusinek H, Convit A, de Leon MJ. Magnetic resonance and PET studies in the early diagnosis of alzheimer's disease. Expert Rev Neurother. 2004 ; 4 (5). 831-849
10. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset alzheimer's dementia. Proc Natl Acad Sci U S A. 2004 ; 101 (1). 284-289
11. Hoyer S. Oxidative energy metabolism in alzheimer brain. studies in early-onset and late-onset cases. Mol Chem Neuropathol. 1992 ; 16 (3). 207-224
12. McCall AL. The impact of diabetes on the CNS. Diabetes. 1992 ; 41 (5). 557-570
13. Craft S, Zallen G, Baker LD. Glucose and memory in mild senile dementia of the alzheimer type. J Clin Exp Neuropsychol. 1992 ; 14 (2). 253-267
14. Craft S, Dagogo-Jack SE, Wiethop BV, et al. Effects of hyperglycemia on memory and hormone levels in dementia of the alzheimer type: a longitudinal study. Behav Neurosci. 1993 ; 107 (6). 926-940
15. Manning CA, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the alzheimer's type. Neurobiol Aging. 1993 ; 14 (6). 523-528
16. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in alzheimer's disease determined by dynamic FDG-PET.. 1996 ; 37 (2). 201-208
17. Wang D, Pascual JM, Yang H, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol. 2005 ; 57 (1). 111-118
18. about-axona.com. http://www.about-axona.com/wordpress/wp-content/uploads/ prescribinginformation.pdf. Updated 2012. Accessed June 4, 2012.
19. Henderson ST. Ketone bodies as a therapeutic for alzheimer's disease. Neurotherapeutics. 2008 ; 5 (3). 470-480
20. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999 ; 15 (6). 412-426
21. Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004 ; 25 (3). 311-314
22. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 ; 6: 31
23. Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL-1β on a ketone body based therapeutic on cognition in mild to moderate alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet. 2011 ; 12: 137
24. Craft S, Asthana S, Schellenberg G, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci. 2000 ; 903: 222-228
25. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in alzheimer disease clinical trials. Arch Neurol. 2007 ; 64 (9). 1323-1329
26. Meng X, D'Arcy C. Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses. PLoS One. 2012 ; 7 (6). e38268
27. Sattler C, Toro P, Schonknecht P, Schroder J. Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and alzheimer's disease. Psychiatry Res. 2012 ; 196 (1). 90-95
28. Shea TB, Remington R. Positive argument for debate in J neural transmission: Alzheimer's disease: are we intervening too late? yes, by years if not decades. J Neural Transm. 2012 ; 119 (12). 1529-1532
29. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain metabolism during fasting. J Clin Invest. 1967 ; 46 (10). 1589-1595
30. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995 ; 9 (8). 651-658
31. VanItallie TB, Nufert TH. Ketones: metabolism's ugly duckling. Nutr Rev. 2003 ; 61 (10). 327-341
32. Hoyer S. Is sporadic alzheimer disease the brain type of non-insulin dependent diabetes mellitus? a challenging hypothesis. J Neural Transm. 1998 ; 105 (4-5). 415-422
33. Craft S.. Insulin resistance and alzheimer's disease pathogenesis: Potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007 ; 4 (2). 147-152
34. Shah RC. Medical foods for alzheimer's disease. Drugs Aging. 2011 ; 28 (6). 421-428
35. St Onge MP, Bosarge A, Goree LL, Darnell B. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008 ; 27 (5). 547-552
36. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of alzheimer's and parkinson's disease. Proc Natl Acad Sci U S A. 2000 ; 97 (10). 5440-5444
37. Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of alzheimer's disease. Nutr Metab (Lond). 2005 ; 2: 28
38. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of parkinson disease. J Clin Invest. 2003 ; 112 (6). 892-901
39. Suzuki M, Suzuki M, Sato K, et al. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001 ; 87 (2). 143-150
40. Suzuki M, Suzuki M, Kitamura Y, et al. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn J Pharmacol. 2002 ; 89 (1). 36-43
41. Prins ML, Lee SM, Fujima LS, Hovda DA. Increased cerebral uptake and oxidation of exogenous betaHB improves ATP following traumatic brain injury in adult rats. J Neurochem. 2004 ; 90 (3). 666-672
42. Mejia Toiber J, Montiel T, Massieu L. D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo. Neurochem Res. 2006 ; 31 (12). 1399-1408
43. Kim do Y, Davis LM, Sullivan PG, et al. Ketone bodies are protective against oxidative stress in neocortical neurons. J Neurochem. 2007 ; 101 (5). 1316-1326